Publication date: Aug 24, 2024
2-Hydroxyethyl methacrylate (HEMA) was added into the European baseline series (EBS) in 2019. There is limited data regarding the frequency, relevance, and sources of exposure to HEMA. To investigate the frequency and clinical relevance of positive reactions to HEMA in the EBS in Israel, and explore sources of exposure. Retrospective cohort study that included all patients who underwent patch testing with the EBS in a tertiary center in Israel between 2020 and 2023. Positive reactions to HEMA were stratified by sex, six age groups, and year of study. Sources of exposure to HEMA as well as occupational data were recorded. A total of 1671 consecutive patients underwent HEMA patch testing, with 135 (8. 1%) showing positive reactions to HEMA (130 females, 5 males). The prevalence in women (11. 0%) was significantly higher compared to men (1. 0%) (p
| Concepts | Keywords |
|---|---|
| Clinical | 2‐hydroxyethyl methacrylate |
| Dermatitis | ACD |
| Hydroxyethyl | acrylic nails |
| Israel | acryls |
| Women | allergic contact dermatitis |
| HEMA |
Semantics
| Type | Source | Name |
|---|---|---|
| drug | DRUGBANK | Acrylic Acid |
| disease | VO | frequency |
| disease | MESH | clinical relevance |
| disease | MESH | allergic contact dermatitis |